Identification of high risk anaplastic gliomas by a diagnostic and prognostic signature derived from mRNA expression profiling.

PubWeight™: 0.82‹?›

🔗 View Article (PMID 26436699)

Published in Oncotarget on November 03, 2015

Authors

Chuan-Bao Zhang1,2,3,4, Ping Zhu5, Pei Yang1,2,3,4, Jin-Quan Cai6, Zhi-Liang Wang2,3,4, Qing-Bin Li6, Zhao-Shi Bao2,4, Wei Zhang2,4, Tao Jiang1,2,3,4

Author Affiliations

1: Department of Molecular Neuropathology, Beijing Neurosurgical Institute, Capital Medical University, Beijing, China.
2: Department of Neurosurgery, Beijing Tiantan Hospital, Capital Medical University, Beijing, China.
3: Center of Brain Tumor, Beijing Institute for Brain Disorders, Beijing, China.
4: China National Clinical Research Center for Neurological Diseases, Beijing, China.
5: Department of Otolaryngology, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China.
6: Department of Neurosurgery, The Second Affiliated Hospital of Harbin Medical University, Harbin, China.

Articles cited by this

The 2007 WHO classification of tumours of the central nervous system. Acta Neuropathol (2007) 49.11

Integrated genomic analysis identifies clinically relevant subtypes of glioblastoma characterized by abnormalities in PDGFRA, IDH1, EGFR, and NF1. Cancer Cell (2010) 39.09

Molecular subclasses of high-grade glioma predict prognosis, delineate a pattern of disease progression, and resemble stages in neurogenesis. Cancer Cell (2006) 21.66

Time-dependent ROC curves for censored survival data and a diagnostic marker. Biometrics (2000) 10.63

Adjuvant procarbazine, lomustine, and vincristine improves progression-free survival but not overall survival in newly diagnosed anaplastic oligodendrogliomas and oligoastrocytomas: a randomized European Organisation for Research and Treatment of Cancer phase III trial. J Clin Oncol (2006) 6.65

Phase III trial of chemotherapy plus radiotherapy compared with radiotherapy alone for pure and mixed anaplastic oligodendroglioma: Intergroup Radiation Therapy Oncology Group Trial 9402. J Clin Oncol (2006) 4.88

Adjuvant procarbazine, lomustine, and vincristine chemotherapy in newly diagnosed anaplastic oligodendroglioma: long-term follow-up of EORTC brain tumor group study 26951. J Clin Oncol (2012) 4.70

NOA-04 randomized phase III trial of sequential radiochemotherapy of anaplastic glioma with procarbazine, lomustine, and vincristine or temozolomide. J Clin Oncol (2009) 4.32

Phase III trial of chemoradiotherapy for anaplastic oligodendroglioma: long-term results of RTOG 9402. J Clin Oncol (2012) 3.96

GSVA: gene set variation analysis for microarray and RNA-seq data. BMC Bioinformatics (2013) 2.29

Understanding high grade glioma: molecular mechanism, therapy and comprehensive management. Cancer Lett (2013) 1.82

Molecular classification of gliomas based on whole genome gene expression: a systematic report of 225 samples from the Chinese Glioma Cooperative Group. Neuro Oncol (2012) 1.66

A long non-coding RNA signature in glioblastoma multiforme predicts survival. Neurobiol Dis (2013) 1.42

Prediction of survival in diffuse large B-cell lymphoma based on the expression of 2 genes reflecting tumor and microenvironment. Blood (2011) 1.41

Whole-genome microRNA expression profiling identifies a 5-microRNA signature as a prognostic biomarker in Chinese patients with primary glioblastoma multiforme. Cancer (2012) 1.33

DNA methylation biomarkers in cancer: progress towards clinical implementation. Expert Rev Mol Diagn (2012) 1.24

Management and survival rates in patients with glioma in China (2004-2010): a retrospective study from a single-institution. J Neurooncol (2013) 1.12

The genetic landscape of anaplastic astrocytoma. Oncotarget (2014) 1.09

Performance evaluation of the DNA methylation biomarker SHOX2 for the aid in diagnosis of lung cancer based on the analysis of bronchial aspirates. Int J Oncol (2011) 1.06

DNA methylation of the homeobox genes PITX2 and SHOX2 predicts outcome in non-small-cell lung cancer patients. Diagn Mol Pathol (2012) 1.04

The evolutionarily conserved G protein-coupled receptor SREB2/GPR85 influences brain size, behavior, and vulnerability to schizophrenia. Proc Natl Acad Sci U S A (2008) 0.95

Whole-genome mRNA expression profiling identifies functional and prognostic signatures in patients with mesenchymal glioblastoma multiforme. CNS Neurosci Ther (2013) 0.90

A chemical small molecule induces mouse embryonic stem cell differentiation into functional vascular endothelial cells via Hmbox1. Stem Cells Dev (2012) 0.86

HMBOX1 negatively regulates NK cell functions by suppressing the NKG2D/DAP10 signaling pathway. Cell Mol Immunol (2011) 0.86

Role of Hmbox1 in endothelial differentiation of bone-marrow stromal cells by a small molecule. ACS Chem Biol (2010) 0.84

SREB2/GPR85, a schizophrenia risk factor, negatively regulates hippocampal adult neurogenesis and neurogenesis-dependent learning and memory. Eur J Neurosci (2012) 0.83

Classification and management of anaplastic gliomas. Curr Opin Neurol (2009) 0.82

HMBOX1, homeobox transcription factor, negatively regulates interferon-γ production in natural killer cells. Int Immunopharmacol (2011) 0.79

Effect of schizophrenia risk-associated alleles in SREB2 (GPR85) on functional MRI phenotypes in healthy volunteers. Neuropsychopharmacology (2012) 0.77